Leadership from the Innovation & Value Initiative, along with experts in mental health and a representative from employer purchasing group, discuss strategies for creating value-based decisions in mental health coverage.
In the latest Matters in Managed Care webinar, experts discussed the current state of mental health care, including the growing consensus on the need for change, strategies to provide high value care, and opportunities for collaboration among payers and other healthcare stakeholders.
The speakers highlighted common challenges for employers and payers regarding coverage for mental health care; discussed common definitions of value for payers, employers, and people with lived experience; shared strategies to incentivize high-value interventions for mental health care; and identified opportunities for future collaboration.
The speakers were:
In segment 1, they discussed how mental health affects everyone.
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Inspiring Clinicians to Take Action on Closing Diabetes Care Gaps
December 7th 2023Clinicians and leaders from Duke University convened in Durham, North Carolina, to discuss unmet needs in the care of patients with diabetes and opportunities to close those gaps through coordination, education, support, and technology.
Read More
Promoting Health Equity and Resiliency in Trauma-Affected Communities
January 31st 2023On this episode of Managed Care Cast, we speak with Reverend Paul Abernathy, CEO of the Neighborhood Resilience Project and board member of UPMC for You, who discusses his experiences in promoting health and resiliency in trauma-affected communities, as well as challenges related to access and accessibility of care and medical mistrust.
Listen
Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent
December 5th 2023The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Read More